Original articleThyroid Outcome During Long-Term Gonadotropin-Releasing Hormone Agonist Treatments for Idiopathic Precocious Puberty
Section snippets
Patient population
To assess thyroid function during long-term GnRHa treatment, we retrospectively analyzed clinical data of CPP girls attended as outpatients at the Pediatric Endocrine Center of Pisa between 1998 and 2004. After local Institutional Review Board approval, informed consent was obtained for all parents of patients prior to the study. The inclusion criteria in the study were: (1) being a female affected by idiopathic CPP; (2) being continuously GnRHa-treated for more than 37 months; (3) one IM
Results
At the start of GnRHa treatment, the auxological characteristics of CPP subjects treated with TR and LA were statistically similar (p > .05; Table 1). During GnRHa treatment, down-regulation of the pituitary-gonadal axis was confirmed by suppressed LH, FSH, and E2 levels. They fell significantly during TR treatment with serum values of .76 ± .5 IU/L, 1.23 ± .6 IU/L, and 13.6 ± 1.5 pg/mL, respectively (p < .001 for all three hormones as compared with their levels before TR treatment). During LA
Discussion
GnRHa drugs are used in the treatment of a wide variety of sex hormone-related diseases, including uterine leiomyoma, endometriosis, prostate, and breast cancer [1], [2]. In the pediatric population, GnRHa drugs are mostly used to delay the effects of premature awakening of the hypothalamic-pituitary-gonadal axis in children with CPP [3], [5], [6].
In our Pediatric Endocrine Center, CPP patients are determined for GnRHa suppression of gonadotropin-ovary axis every 4–6 months by circulating LH,
References (27)
- et al.
The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women
Fertil Steril
(1995) - et al.
Pituitary function before, during, and after chronic gonadotropin-releasing hormone agonist therapy
Fertil Steril
(1992) - et al.
Autoimmune thyroiditis during leuprolide acetate treatment
J Pediatr
(2004) - et al.
A crossover study of triptorelin and leuprorelin acetate
Fertil Steril
(2000) - et al.
Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors
J Endocrinol
(2002) - et al.
Clinical use of GnRH analogues
Clin Endocrinol
(2002) - et al.
Gonadotropin-releasing hormone analogue treatment for precocious pubertyTwenty years of experience
Endocr Dev
(2005) - et al.
Pharmacokinetics and pharmacodynamics of GnRH agonists: Clinical implications in pediatrics
J Pediatr Endocrinol Metab
(2000) - et al.
Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
Eur J Pediatr
(1998) - et al.
Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: Final height results
Horm Res
(2002)
Treatment of central precocious puberty with depot leuprorelin
Eur J Endocrinol
Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: Evaluation of effectiveness of treatment and recovery of gonadal function
J Clin Endocrinol Metab
Increased final height in precocious puberty after long-term treatment with LHRH agonists: The NIH experience
J Clin Endocrinol Metab
Cited by (11)
Comparative aspects of GnRH-Stimulated signal transduction in the vertebrate pituitary – Contributions from teleost model systems
2018, Molecular and Cellular EndocrinologyCitation Excerpt :GnRH also enhanced TSH release from adult bullfrog pituitary cells but not from larval pituitary cells (Okada et al., 2009). Treatment with desensitizing doses of mGnRH agonists significantly reduced free T3 levels as well as free T3 to free T4 ratios in children with idiopathic precocious puberty although changes in TSH levels were not significant (Massart et al., 2007). On the other hand, mGnRH stimulated ACTH secretion in some patients with hypothyroidism (Ban et al., 2000) and from perifused pituitary tumor cells obtained from patients with Cushing's disease (Oki et al., 1981).
High Growth Rate of Girls with Precocious Puberty Exposed to Estrogenic Mycotoxins
2008, Journal of PediatricsCitation Excerpt :After approval from the local institutional review board, informed consent was obtained from all the parents of patients before the study. Diagnostic criteria for CPP were consistent with a recent study.17 At CPP diagnosis, all 32 patients (group A and B) had a history of increased growth velocity, Tanner breast stage of at least 2, and bone age (BA) was advanced >1 year; luteinizing horomone, and follicle-stimulating hormone responses to the gonadatropin-releasing hormone (GnRH) stimulation test (100 mg/m2, intravenous bolus dose) were in the pubertal range.18
The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis
2024, Journal of Pediatric Endocrinology and MetabolismHyperprolactinemia in Female Children and Adolescents
2022, Journal fur Gynakologische EndokrinologieIs gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
2020, Interventional Medicine and Applied ScienceSerum levels of thyroid stimulating hormone and luteinizing hormone are decreased in girls with central precocious puberty after 12-month gnrh agonist treatment
2020, Tohoku Journal of Experimental Medicine